دورية أكاديمية
Proposal for individualized dosing of eculizumab in atypical haemolytic uraemic syndrome: patient friendly and cost-effective.
العنوان: | Proposal for individualized dosing of eculizumab in atypical haemolytic uraemic syndrome: patient friendly and cost-effective. |
---|---|
المؤلفون: | Ter Avest M; Department of Pharmacy, Radboud Institute for Health Sciences, Radboud University Medical Centre, Nijmegen, The Netherlands., Bouwmeester RN; Department of Paediatric Nephrology, Radboud Institute for Molecular Life Sciences, Amalia Children's Hospital, Radboud University Medical Centre, Nijmegen, The Netherlands., Duineveld C; Department of Nephrology, Radboud University Medical Centre, Nijmegen, The Netherlands., Wijnsma KL; Department of Paediatric Nephrology, Radboud Institute for Molecular Life Sciences, Amalia Children's Hospital, Radboud University Medical Centre, Nijmegen, The Netherlands., Volokhina EB; Department of Paediatric Nephrology, Radboud Institute for Molecular Life Sciences, Amalia Children's Hospital, Radboud University Medical Centre, Nijmegen, The Netherlands.; Department of Laboratory Medicine, Radboud University Medical Centre, Nijmegen, The Netherlands., van den Heuvel LPWJ; Department of Paediatric Nephrology, Radboud Institute for Molecular Life Sciences, Amalia Children's Hospital, Radboud University Medical Centre, Nijmegen, The Netherlands.; Department of Laboratory Medicine, Radboud University Medical Centre, Nijmegen, The Netherlands., Burger DM; Department of Pharmacy, Radboud Institute for Health Sciences, Radboud University Medical Centre, Nijmegen, The Netherlands., Wetzels JFM; Department of Nephrology, Radboud University Medical Centre, Nijmegen, The Netherlands., van de Kar NCAJ; Department of Paediatric Nephrology, Radboud Institute for Molecular Life Sciences, Amalia Children's Hospital, Radboud University Medical Centre, Nijmegen, The Netherlands., Ter Heine R; Department of Pharmacy, Radboud Institute for Health Sciences, Radboud University Medical Centre, Nijmegen, The Netherlands. |
مؤلفون مشاركون: | CUREiHUS study group |
المصدر: | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association [Nephrol Dial Transplant] 2023 Feb 13; Vol. 38 (2), pp. 362-371. |
نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
اللغة: | English |
بيانات الدورية: | Publisher: Oxford University Press Country of Publication: England NLM ID: 8706402 Publication Model: Print Cited Medium: Internet ISSN: 1460-2385 (Electronic) Linking ISSN: 09310509 NLM ISO Abbreviation: Nephrol Dial Transplant Subsets: MEDLINE |
أسماء مطبوعة: | Publication: Oxford : Oxford University Press Original Publication: [Berlin ; New York, NY] : Springer International, [c1986- |
مواضيع طبية MeSH: | Atypical Hemolytic Uremic Syndrome*/drug therapy, Humans ; Cost-Benefit Analysis ; Antibodies, Monoclonal, Humanized/therapeutic use |
مستخلص: | Background: Eculizumab is a lifesaving yet expensive drug for atypical haemolytic uraemic syndrome (aHUS). Current guidelines advise a fixed-dosing schedule, which can be suboptimal and inflexible in the individual patient. Methods: We evaluated the pharmacokinetics (PK) and pharmacodynamics (PD) [classical pathway (CP) activity levels] of eculizumab in 48 patients, consisting of 849 time-concentration data and 569 CP activity levels. PK-PD modelling was performed with non-linear mixed-effects modelling. The final model was used to develop improved dosing strategies. Results: A PK model with parallel linear and non-linear elimination rates best described the data with the parameter estimates clearance 0.163 L/day, volume of distribution 6.42 L, maximal rate 29.6 mg/day and concentration for 50% of maximum rate 37.9 mg/L. The PK-PD relation between eculizumab concentration and CP activity was described using an inhibitory Emax model with the parameter estimates baseline 101%, maximal inhibitory effect 95.9%, concentration for 50% inhibition 22.0 mg/L and Hill coefficient 5.42. A weight-based loading dose, followed by PK-guided dosing was found to improve treatment. On day 7, we predict 99.95% of the patients to reach the efficacy target (CP activity <10%), compared with 94.75% with standard dosing. Comparable efficacy was predicted during the maintenance phase, while the dosing interval could be prolonged in ∼33% of the population by means of individualized dosing. With a fixed-dose 4-week dosing interval to allow for holidays, treatment costs will increase by 7.1% and we predict 91% of the patients will reach the efficacy target. Conclusions: A patient-friendly individualized dosing strategy of eculizumab has the potential to improve treatment response at reduced costs. (© The Author(s) 2022. Published by Oxford University Press on behalf of ERA.) |
References: | Pediatrics. 2015 Jun;135(6):e1506-9. (PMID: 25941307) J Nephrol. 2017 Feb;30(1):127-134. (PMID: 26995002) Biol Blood Marrow Transplant. 2016 Feb;22(2):307-315. (PMID: 26456258) Lancet. 2017 Aug 12;390(10095):681-696. (PMID: 28242109) Ther Apher Dial. 2019 Feb;23(1):4-21. (PMID: 30294946) Clin Pharmacokinet. 2020 Jan;59(1):37-49. (PMID: 31452150) Br J Clin Pharmacol. 2021 May;87(5):2236-2246. (PMID: 33118186) Pediatr Nephrol. 2015 Jun;30(6):1039-42. (PMID: 25752761) J Med Econ. 2020 Dec;23(12):1503-1515. (PMID: 33001704) Kidney Int Rep. 2019 Aug 02;4(11):1568-1576. (PMID: 31890998) Clin Pharmacol Ther. 2017 Oct;102(4):671-678. (PMID: 28295239) AAPS J. 2011 Jun;13(2):143-51. (PMID: 21302010) Clin Pharmacokinet. 2019 Jul;58(7):859-874. (PMID: 30758736) Med Decis Making. 2014 Nov;34(8):1016-29. (PMID: 24990825) MAbs. 2015;7(6):1205-11. (PMID: 26337866) Clin Immunol. 2015 Oct;160(2):237-43. (PMID: 26111482) BMC Nephrol. 2019 Apr 10;20(1):125. (PMID: 30971227) Health Technol Assess. 2016 Nov;20(83):1-288. (PMID: 27845027) Front Immunol. 2021 Jan 15;11:612706. (PMID: 33519821) Br J Haematol. 2019 Apr;185(2):297-310. (PMID: 30768680) Clin Exp Immunol. 2017 Feb;187(2):304-315. (PMID: 27784126) Blood. 2021 May 6;137(18):2438-2449. (PMID: 33270832) Pediatr Nephrol. 2019 Nov;34(11):2261-2277. (PMID: 30402748) J Immunol Methods. 2005 Jan;296(1-2):187-98. (PMID: 15680163) Kidney Int. 2016 Mar;89(3):701-11. (PMID: 26880462) Pediatr Nephrol. 2016 Jan;31(1):15-39. (PMID: 25859752) Clin Transl Sci. 2018 Nov;11(6):540-552. (PMID: 29877608) N Engl J Med. 2013 Jun 6;368(23):2169-81. (PMID: 23738544) |
فهرسة مساهمة: | Investigator: E van Kempen; W Altena; E Adang; DJAR Moes; AD van Zuijlen; SP Berger; FJ Bemelman; JW van der Heijden; J van de Wetering; APJ de Vries; P van Paasen; JFM Wetzels; JAE van Wijk; AHM Bouts; EM Dorresteijn; V Gracchi; FAPTH Engels; MG Keijzer-Veen; RWG van Rooij; NCAJ van de Kar Keywords: aHUS; complement; eculizumab; pharmacodynamics; pharmacokinetics |
المشرفين على المادة: | A3ULP0F556 (eculizumab) 0 (Antibodies, Monoclonal, Humanized) |
تواريخ الأحداث: | Date Created: 20220303 Date Completed: 20230214 Latest Revision: 20230918 |
رمز التحديث: | 20240628 |
مُعرف محوري في PubMed: | PMC9923710 |
DOI: | 10.1093/ndt/gfac056 |
PMID: | 35238929 |
قاعدة البيانات: | MEDLINE |
تدمد: | 1460-2385 |
---|---|
DOI: | 10.1093/ndt/gfac056 |